Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Approvals In Brief

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA approves Plavix STEMI sNDA in the midst of sponsors’ patent dispute with Apotex; Bristol-Myers Squibb/Sanofi-Aventis will likely have to compete with generic off-label prescriptions. Barr’s emergency contraceptive Plan B finally gains approval for over-the-counter sales for women age 18 and older. More approvals in brief
Advertisement

Related Content

Bristol/Sanofi Plan sNDA For Plavix Acute MI Subset Indication By Year-End

Topics

Advertisement
UsernamePublicRestriction

Register

PS003391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel